Skip to main content
. 2021 Sep 9;12(6):1501–1512. doi: 10.1002/jcsm.12764

Figure 2.

Figure 2

Impact of FCM on clinical, laboratory, and echocardiographic measures. Development of (A) 6 min walking distance (6MWD), (B) NTproBNP serum concentrations, (C) WHO functional class (WHO‐FC; in the FCM group), and (D) tricuspid annular plane systolic excursion (TAPSE) from baseline to 18 month follow‐up in the FCM vs. control group. Numbers represent mean values ± SEM. *P < 0.05; **P < 0.01 vs. baseline.